Zosano Pharma Corporation

Robbins Arroyo LLP Is Investigating the Officers and Directors of Zosano Pharma Corporation (ZSAN) on Behalf of Shareholders

January 20, 2016 (San Diego, CA & Fremont, CA) – Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Zosano Pharma Corporation (NASDAQCM: ZSAN) violated federal securities laws by issuing materially misleading business information to the investing public. Zosano is a clinical stage specialty pharmaceutical company that develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications.

Zosano Issues Potentially Misleading SEC Filings

In January 2015, Zosano offered more than 6.5 million shares of its common stock at $11.00 per share in connection with its initial public stock offering (“IPO”). However, Zosano’s filings with the U.S. Securities and Exchange Commission in connection with its IPO may have contained untrue statements of material facts or omitted other facts concerning the company’s business and financial prospects. Just one year after its IPO, Zosano common stock has plummeted and closed at just $2.02 per share on January 19, 2016 – almost 82% less than its January 2015 offering price.

Zosano Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: